Hoffmann syndrome

Signs and symptoms

Signs and symptoms include exercise intolerance, muscle fatigue, muscle cramps, myalgia, delayed muscle relaxation (pseudomyotonia), proximal muscle weakness, delayed deep tendon reflexes (hyporeflexia) especially of the ankles, and a pseudoathletic appearance of hypertrophic calf muscles. There may also be bradycardia, mild anemia, dry skin, hoarse voice, and cold intolerance. EMG may be normal, neuropathic, myopathic, or mixed type. Serum CK may be normal or raised. The sign of myoedema (raised muscle tissue in response to percussive tactile stimulus) may be observed. Treatment is thyroid hormone replacement therapy, and prognosis is generally good. Hypertrophic calves typically return to normal after approximately 3 months of treatment.

Cause

It is caused by low thyroid hormones (T3 and T4).

Diagnosis

Muscle biopsy of hypothyroid myopathy shows atrophy of type II (fast-twitch/glycolytic) muscle fibres and a predominance of type I (slow-twitch/oxidative) muscle fibres; as well as abnormally high glycogen accumulation. The reason for the muscle hypertrophy in Hoffmann syndrome is not clearly established; it may be due to altered carbohydrate metabolism, mucoid deposits, or glycosaminoglycan deposits. In an individual diagnosed with Hoffmann syndrome whose hypertrophy did not improve after thyroid hormone replacement therapy, muscle biopsy showed hypertrophy of muscle fibres with increased nuclei, few necrotic fibres and mucoid deposits in places.

Differential diagnoses

Diseases known to have a pseudoathletic appearance of the calves (hypertrophy or pseudohypertrophy), including exercise intolerance and/or muscle weakness:

• Kocher–Debré–Semelaigne syndrome (childhood-onset hypothyroid myopathy),
• Glycogen storage disease (GSD-V, & late-onset GSD-II),
• Non-dystrophic myotonias and pseudomyotonias (such as Myotonia congenita and Brody disease),
• Limb-girdle muscular dystrophy,
• Duchenne and Becker muscular dystrophy
• Focal myositis,
• Sarcoid granulomas, and
• Amyloid deposits in muscles Thyroid metabolism can be disrupted secondary to a primary disease. A common comorbidity of the metabolic myopathy McArdle disease (Glycogen storage disease type V) is hypothyroidism. It is also a comorbidity of late-onset Pompe disease (Glycogen storage disease type II). As both hyper- and hypothyroidism disrupts muscle glycogen metabolism, it is important to keep in mind differential diagnoses and their comorbidities when trying to determine whether signs and symptoms are either primary or secondary disease.

Management

References

References

1. "Myopathies associated with thyroid disease".
2. (March 2013). "Myoedema: A clinical pointer to hypothyroid myopathy.". Indian Journal of Endocrinology and Metabolism.
3. (October 2014). "Hoffman's syndrome - A rare facet of hypothyroid myopathy.". Journal of Neurosciences in Rural Practice.
4. (October 2005). "Hoffmann syndrome: presentation in hypothyroidism.". Journal of Postgraduate Medicine.
5. (September 2003). "Hoffman's syndrome: pseudohypertrophic myopathy as initial manifestation of hypothyroidism. Case report.". Arquivos de Neuro-psiquiatria.
6. (2020-09-01). "Endocrine myopathies: clinical and histopathological features of the major forms". Acta Myologica.
7. (2023). "Hypothyroid Myopathy". StatPearls Publishing.
8. (1989-01-15). "Effects of hypothyroidism on the sensitivity of glycolysis and glycogen synthesis to insulin in the soleus muscle of the rat.". Biochemical Journal.
9. (November 2018). "Non-osteogenic muscle hypertrophy in children with McArdle disease". Journal of Inherited Metabolic Disease.
10. (July 2016). "Calf Muscle Hypertrophy in Late Onset Pompe's Disease". Archives of Medicine and Health Sciences.
11. (October 2020). "Guidelines on clinical presentation and management of nondystrophic myotonias". Muscle & Nerve.
12. de Visser, Marianne. (2020-12-01). "Late-onset myopathies: clinical features and diagnosis". Acta Myologica.
13. (2020-11-24). "Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)". Orphanet Journal of Rare Diseases.
14. (December 2021). "Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group". Neuromuscular Disorders.
15. (September 2016). "Hypothyroidism in late-onset Pompe disease". Molecular Genetics and Metabolism Reports.
16. (2021). "Recommendations for Infantile-Onset and Late-Onset Pompe Disease: An Iranian Consensus". Frontiers in Neurology.
17. (April 1986). "Effect of hyperthyroidism on fibre-type composition, fibre area, glycogen content and enzyme activity in human skeletal muscle". Clinical Physiology.
18. Brenta, Gabriela. (2011). "Why can insulin resistance be a natural consequence of thyroid dysfunction?". Journal of Thyroid Research.